NRX Pharmaceuticals (NRXP) logo

NRX Pharmaceuticals (NRXP) stock

Pre-market
$2.15
-1.83%

Nervous system medicines, worth $98.7MSmall-cap biotech

Close $2.19 -3.95%

Why is NRXP down?

Down 4.4% on Nov 2, and still 4% under its Oct 30 close.

  • It reported a press release in an SEC filing that day.

Sources: Price history, Nov 2, 2026; SEC filing, Nov 2, 2026

−2Long-term trend below a falling 200-day average, down over one year

Tell me next time NRXP moves

Free account, no card. An optional alert when NRXP moves or its score changes.Pro, 7 days free with a card. An optional alert when NRXP moves or its score changes.

Or see it live, free until tomorrow morning. No account.
1 more reason, free with an account →1 more reason why NRXP fell on Nov 2, from its filings, with how the business stands, the timeline, and its peers, for Pro members.
Quality Score
-6
Poor
In its industry
#218of 270
Checks firing
2of 14
Trending down
From 52-week high
-56.7%
under its best in a year

NRXP's Quality Score rose 1 point on Fri, Nov 13, to -6. It had its calmest day in a week.

Follow NRXP's trial news. Pro members can get an alert when NRX Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when NRXP files news on its trialSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2027“…on the drug packaging matter, the Company is now poised to finalize its NDA, aiming for 2027 approval…”Filing with regulators · SEC filing · Aug 17
Cash$26.7M, about 5 quarters at the last year's spendingOn Jun 30

Key facts on NRXP

Key facts on NRXP
Holding it back109.9% more shares than a year ago
Latest filing8-K, Oct 5 Signed a material agreement
1 more reason behind NRXP's -6, free with an account →3 more reasons behind NRXP's -6, for Pro members.

NRXP in the news

ReportReports today, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 of its last 3 reports, +6.7% on average. Past reports ›

Big story

Fri Oct 30: FDA

NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of

Reported by GlobeNewswire · covered by 7 outlets

Get an alert on NRXP's next big story →

Outlet counts from the GDELT Project. The move is what NRXP did that session, not a claim about why.

What's next

Tue Nov 17: Q3 2026 Earnings Conference CallDate confirmed.

1 more date ahead: the meeting, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$26.7M, about 5 quarters at the last year's spendingOn Jun 30

NRXP catalysts

Coming up

After its last 3 reports it closed +6.7% on average, higher 2 of 3 times.

5 past catalysts since 2021, with sizes and sources, for Pro members.

What's next for NRXP, and how long its cash lasts

Next step the company has named

2027“With alignment on the drug packaging matter, the Company is now poised to finalize its NDA, aiming for 2027 approval.”Filing with regulators · SEC filing · Aug 17

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway
SPARC-TMSPhase 2/3 · Recruiting · 240 people · main data estimated Dec 31, 2027 · NCT07227103

For Pro members: 63 filings.

Cash runway Jun 30 balance sheet

About 5 quarters

$26.7M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Jun 20, 2025)
  • At-the-market share sales program (424B5, filed Feb 17, 2026)

For Pro members: 11 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Jonathan Javitt’s 10 filings and quotes.

Get an alert when NRXP files news on its trialA free account. No card.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 150 dates, ranked →

How NRXP ranks in Biotech

NRXP is #218 of 270 by Quality Score.

How NRXP ranks in Biotech
RankStockQuality Score
218NRX Pharmaceuticals (NRXP) logoNRXPNRX Pharmaceuticals-6

Net income over four quarters: NRXP -$23.5M, INO -$71.1M.

More in Biotech

When does NRXP report earnings, and what happens after?

Reports Mon Nov 16, after the close (today). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What NRXP reported on Aug 17, 2026

The quarter

The figures are not read from the release yet.

“The change was primarily driven by certain research and development costs related to the acquisition of certain assets which management believes will drive significant long-term value for shareholders, as well as increased selling, general and administrative costs including, but not limited to, the addition of key personnel and other expenses related to the Company's anticipated commercial launch of its ANDA for preservative-free ketamine.”

The filing on EDGAR

Where the sales came from

NRXP's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value
$98.7M
today
Sales
$3.4M
last 12 months

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on NRXP: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+20.3%-5.0%+4.9%
Mar 24May 18Aug 17
ReportedGapReaction5
days
Aug 17, 2026Before open-5.2%+4.9%+8.9%
May 18, 2026Before open+3.4%-5.0%-1.8%
Mar 24, 2026Before open+6.8%+20.3%+18.1%

NRXP closed higher after 2 of its last 3 reports.

Everyone reporting earnings this week

NRXP sales and profit by year

Profit by year

Sales grew in 2025, to $1.2M. It lost money in both years.

NRXP has 2 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on NRXP, and all 14 on every stock.Get in free →

NRXP RSI on Nov 13: 37.0, below its 50-day and 200-day averages

Not scored

RSI 37.0, MACD above signal, below both averages. Not scored.

The deep dive on NRXP

7 more findings on NRXP, each with its source, for Pro members.

NRXP share count over time

110% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of NRXP outstanding, as filed
Shares
outstanding
As
of
43.3MAug 14, 2026
36.2MMay 15, 2026
33.1MMar 23, 2026
28.1MNov 13, 2025
Offerings, shelves, and splits of NRXP, from its filings
From its
filings
Filed
Raised $20M in a sale of shares, about 20% of its market valueJun 3, 2026
Set up an at-the-market program for up to $20M of shares, about 20% of its market valueFeb 17, 2026
Priced a sale of sharesDec 22, 2025
Priced a sale of sharesAug 18, 2025

9 more offerings on file, for Pro members.

About NRX Pharmaceuticals

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

29 employeesWilmington, DEnrxpharma.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on NRXP and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn NRXP's score around: 8 things
  • 17 more filings explained, a plain line each
  • 4 more things pulling NRXP's score down
See NRXP's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 16, 2026: NRXP's Quality Score is -6 (Poor), #218 of 270 in Biotech.

What does NRXP's Quality Score say?

NRXP scores -6 today, which Breakaway calls Poor. It is #218 of 270 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 4.4% on Nov 2, and still 4% under its Oct 30 close. Cash lasts about 5 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is NRXP's Quality Score?

NRXP scores -6 today, which Breakaway calls Poor (below zero). That is #218 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NRXP's -6.

When does NRXP report earnings?

Reports Mon Nov 16, after the close, a date the company confirmed. NRXP closed higher after 2 of its last 3 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,145 stocks ranked

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

What's next for NRX Pharmaceuticals: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.